High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis

Table 1

Baseline characteristics and design variables of eligible studies.

Article	Country	Year	Number of patients	Age: mean ± SD/median (range)	Follow-up: mean ± SD/median (range)	Cut-off point	Outcome	Study quality
Takeuchi et al. [22]	Japan	2017	296	NR	Mean: 41	162.28	DFS: 2.61 (1.07–6.36)	7
Asano et al. [20]	Japan	2016	177	NR	Range: 1.2–72	150	DFS: 2.84 (1.37–5.91); OS: 2.62 (1.09–6.34)	7
Liu et al. [21]	China	2016	318	Median: 45 (19–71)	Median: 58.1 (5.9–136.1)	147	DFS: 1.18 (0.9–1.55); OS: 1.30 (0.95–1.79)	6
Allan et al. [19]	Costa Rica	2016	172	Mean: 54.2 ± 12.7	Median: 79.3 (2–90)	250	DFS: 4.13 (1.60–10.71); OS: 3.86 (1.51–9.89)	7
Ulas et al. [18]	Turkey	2015	187	Mean: 51.4 ± 10.7	Median: 26.0 (6.0–84.0)	161.28	DFS: 0.89 (0.42–1.88); OS: 1.88 (0.57–6.21)	7
Koh et al. [15]	Malaysia	2015	1435	Median: 52	NR	185	DFS: 1.25 (1.04–1.52)	6
Gunduz et al. [32]	Turkey	2015	62	Median: 52 (24–73)	Median: 48.4	200	DFS: 2.35 (1.33–4.16)	6
Yao et al. [33]	China	2014	608	Mean: 52.4 ± 10.8; range: 26–86	Median: 42 (8–62)	107.64	DFS: 1.33 (0.79–2.25); OS: 2.54 (1.00–6.45)	6
Krenn-Pilko et al. [16]	Austria	2014	793	Mean: 57.9 ± 12.2	Median: 98 ± 29.2	292	DFS: 2.03 (1.03–4.02); OS: 1.92 (1.01–3.67)	7
Cihan et al. [17]	Turkey	2014	350	Mean: 55.2 ± 0.3; range: 26–86	Range: 0.3–112	160	DFS: 0.90 (0.50–1.70); OS: 0.70 (0.40–1.40)	6
Azab et al. [34]	USA	2013	437	Mean: 63.6	Mean: 60 ± 0.7	185	OS: 2.90 (1.84–4.58)	7
Cordiner et al. [35]	UK	2011	707	NR	Median: 48.1	NR	DFS: 0.96 (0.58–1.59)	NR

Note. DFS: disease-free survival; NR: not reported; OS: overall survival; PLR: platelet to lymphocyte ratio; SD: standard deviation; UK: United Kingdom; USA: United States of America.